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Abstract
Background: In recent years, a major increase in the occurrence of drug resistant falciparum malaria has
been reported. Choline analogs, such as the bisthiazolium T4, represent a novel class of compounds with
strong potency against drug sensitive and resistant P. falciparum clones. Although T4 and its analogs are
presumed to target the parasite's lipid metabolism, their exact mechanism of action remains unknown.
Here we have employed transcriptome and proteome profiling analyses to characterize the global
response of P. falciparum to T4 during the intraerythrocytic cycle of this parasite.
Results: No significant transcriptional changes were detected immediately after addition of T4 despite the
drug's effect on the parasite metabolism. Using the Ontology-based Pattern Identification (OPI) algorithm
with an increased T4 incubation time, we demonstrated cell cycle arrest and a general induction of genes
involved in gametocytogenesis. Proteomic analysis revealed a significant decrease in the level of the
choline/ethanolamine-phosphotransferase (PfCEPT), a key enzyme involved in the final step of synthesis of
phosphatidylcholine (PC). This effect was further supported by metabolic studies, which showed a major
alteration in the synthesis of PC from choline and ethanolamine by the compound.
Conclusion: Our studies demonstrate that the bisthiazolium compound T4 inhibits the pathways of
synthesis of phosphatidylcholine from choline and ethanolamine in P. falciparum, and provide evidence for
post-transcriptional regulations of parasite metabolism in response to external stimuli.
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Malaria remains a major public health problem in many
parts of the world. Emergence and spread of resistance to
widely accessible and inexpensive antimalarials make the
development of novel therapeutic approaches an urgent
task [1,2]. Plasmodium falciparum causes the most severe
form of the disease and has a devastating effect on the
lives of millions. Intensive asexual multiplication of the
parasite occurs in human erythrocytes and is responsible
for the symptoms associated with human malaria. During
its 48-hour intraerythrocytic life cycle, the parasite under-
goes major morphological and metabolic changes fol-
lowed by nuclear division, cytokinesis and merogony to
generate up to 36 new daughter parasites. Accordingly, the
parasite produces and transports large amounts of lipid
precursors and actively uses them to synthesize the mem-
brane components needed during its rapid development
and multiplication. Phosphatidylcholine (PC) is the
major phospholipid in P. falciparum membranes and its
content increases by approximately six-fold during the
parasite's intraerythrocytic life cycle [3,4]. Because of its
essential function in parasite development, multiplication
and survival, its synthesis has long been viewed as an ideal
target for the development of new antimalarial drugs [5].
Cell biological studies revealed that the synthesis of this
phospholipid occurs via two major metabolic pathways:
the de novo choline pathway and the serine decarboxyla-
tion-phospho-ethanolamine methylation (SDPM) path-
way (Figure 1). The de novo choline pathway is initiated by
the transport of choline from host plasma followed by
three enzymatic reactions that lead to the incorporation of
this precursor into PC. The SDPM pathway initiates from
serine either transported from the host plasma or present
within infected erythrocytes as a result of active degrada-
tion of the erythrocyte proteins by parasite specific pro-
teases [6]. Serine is then subjected to five enzymatic
Phosphatidylcholine biosynthesis pathways in P. falciparumFigure 1
Phosphatidylcholine biosynthesis pathways in P. falciparum. The figure includes relevant steps presented in the results 
and discussion. Enzyme and lipid abbreviations described in the figures are as followed: PC: Phosphatidylcholine; PE: Phos-
phatidylethanolamine; PS: phosphatidylserine; PI: Phosphatidylinositol; DAG: Diacylglycerol; SDPM pathway: Serine Decar-
boxylation-Phospho-ethanolamine Methylation; PfSD: Serine-decarboxylase; PfEK: Ethanolamine kinase; PfPMT: 
phosphoethanolamine N-methyltransferase; PfCK: Choline kinase; PfCCT: CTP-phosphocholine cytidylyltransferase; 
PfCEPT: CDP choline-choline/ethanolamine phosphotransferase protein.Page 2 of 15
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phoethanolamine transmethylation (phosphoeth-
anolamine N-methyltransferase, PfPMT), are plant-like,
while the last two steps are shared with the CDP-choline
pathway (Figure 1) [6-8]. Because of the predicted essen-
tial role of phospholipids in the parasite's intraerythro-
cytic development and multiplication, several efforts have
been made to synthesize lipid-based inhibitors as an alter-
native arsenal to fight malaria. Bisquaternary ammonium
salts that mimic the structure of the phospholipid precur-
sor choline have been shown to target membrane biogen-
esis in P. falciparum by blocking the biosynthesis of PC.
The first generation of these compounds consisted of
mono- and bis-quaternary ammonium salts [9,10], and
their lead compound G25 efficiently inhibited the growth
of drug-resistant strains of P. falciparum in vitro, [11], and
eliminated Plasmodium infection without recrudescence in
rodent [12] and primate models [13] at very low doses.
Further structural optimization of this first generation of
compounds produced the bis-thiazolium compounds T3
and T4, which, at very low doses, exerted a very rapid cyto-
toxic effect against malaria parasites in vitro. These com-
pounds cleared malaria infection in murine and primate
models with no recrudescence [14]. A clinical candidate,
T3/SAR97276, has recently been advanced to clinical
development in humans for treatment of severe malaria
(Vial, unpublished data). To elucidate the mode of action
of this promising class of compounds, we have analyzed
the global effect of T4 on the parasite's transcriptome and
proteome during the P. falciparum intraerythrocytic life
cycle. No significant transcriptional changes were
observed in the genes encoding those enzymes involved
in PC biosynthesis. However, using a proteomic approach
(MS/MS) we detected a down regulation of the choline/
ethanolamine-phosphotransferase protein (MAL6P1.145,
PfCEPT). Metabolic studies further confirmed the specific
action of the compound on the synthesis of PC.
Methods
Parasite cultures, treatments and RNA extraction
P. falciparum parasites (3D7 strain) were cultured in
human O+ erythrocytes as previously described [15].
When necessary, cultures were synchronized (twice within
a 6 hour interval) using sorbitol [16]. T4 was added 48
hours after the first synchronization treatment. Parasites
incubated in complete medium at 8% parasitaemia and
2.5 – 3% haematocrit were treated with varying concentra-
tions of T4. The drug was added to 25 ml cultures at 40 nM
or 125 nM and the parasites were further incubated for 5,
24, 30 and 36 hours, and harvested. Total RNA was pre-
pared as previously described [17]. Parasite synchrony
and morphology were monitored by microscopic analysis
of Giemsa-stained blood smears.
Microarray analyses
The custom high-density oligonucleotide array used in
this study was based on the P. falciparum sequence data
released in July 2001 [17]. The array includes 260,596 25-
mer probes corresponding to 5159 P. falciparum gene
sequences. Probes were synthesized by Affymetrix, Inc.
(Santa Clara, CA) using photosensitive oligonucleotide
chemistry and photolithography. Microarray analysis was
performed as previously described [17]. Briefly, eight
micrograms of total RNA was used for cDNA synthesis. An
oligo-dT primer containing a phage T7 promoter at its 5'
end was used to prime the cDNA synthesis reaction. A sec-
ond strand of cDNA was synthesized and used as a tem-
plate for in vitro transcription in the presence of
biotinylated ribonucleotide following the manufacturer
instructions (Enzo). RNA hybridizations were carried out
with 15 μg of fragmented cRNA at 45°C for 16 hour. The
hybridization solution was removed and the arrays were
stained and washed following Affymetrix protocols.
Arrays were scanned with an emission wavelength of 560
nm at 3 μm resolution using a confocal scanner (Affyme-
trix), and the signal intensity for each sequence feature on
the array was determined using Microarray Suite 5
(Affymetrix).
Semi quantitative RT-PCR
Total RNA was extracted from synchronized untreated and
treated parasites cultures after 24, 30 and 36 hours incu-
bations with T4. RT-PCR was performed as previously
described [18]. Briefly, the RNA was first incubated with
Dnase I (Ambion) at 37°C for 30 min, cleaned using
RNAeasy kit (Qiagen), and quantified. Double strand
cDNA was synthesized using Invitogen superscript RNA
amplification kit. 15 ng of cDNA were loaded into each
RT-PCR reaction using the Gotaq polymerase (Promega).
PCR reactions consisted of 20–35 cycles of amplification
using primers chosen from the 5' coding region of each
selected gene. The following primers were used:
PF14_0708: forward primer 5'- cactgatgatgatattcctc,
reverse primer 3' – attgtgctttaagatgatctc; PF11_0509: for-
ward primer 5' – caagggagttcaatccact, reverse primer 3'-
tcttcttgtgcatcttttgc; Mal7P1.100: forward primer 5' – gaag-
gggatacacttagaat, reverse primer 3' – gttctcgtattaacatgctc;
Mal13P1.129: forward primer 5'- gtggttgtgatattcttctc,
reverse primer 3'- atataccctacacaacgaag; Mal7P1.6: for-
ward primer 5'- cagatgaaacaaatcctactt, reverse primer 3'-
ctaatcattggatggtcttc; Mal13p1.86 (PF13_0092): forward
primer 5'- gagaatcaagatgtagatcc, reverse primer 3'- tctg-
tagttgatacaccttc; PFF1375c (Mal6P1.145): forward primer
5'- atgtgtcttaagcgtaacca reverse primer 3'- gtatggttgta-
caataagcc. Gel images were quantified for relative band
intensity using the NIH ImageJ software.Page 3 of 15
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The Ontology-based Pattern Identification (OPI) algo-
rithm was introduced by Zhou et al. and has been previ-
ously applied to the full life cycle transcriptome data set
[19]. Briefly we applied the OPI analysis to six T4 tran-
scription hybridizations along with previous 38 life cycle
hybridizations. For each gene ontology group, OPI identi-
fies a list of genes that not only share a similar expression
profile, but also show functional enrichment in the target
GO category. A total of 290 clusters were retained after
100 permutation runs (with estimated P ≤ 0.05). The rep-
resentative expression patterns of each OPI clusters were
hierarchically clustered as previously described [20]. This
enabled us to visualize drug-related global expression
changes side-by-side with the transcriptome expression
variation in P. falciparum life cycle.
Protein preparation and MudPIT
Equal amounts of untreated or T4-treated parasites were
analyzed using MudPIT as previously described [21,22].
Briefly, parasite pellets were lysed by osmotic shock in 10
mM Tris-HCl (pH 8.5) and incubated in ice for one hour.
After centrifugation at 18,000 g for 30 min, supernatants
were saved and the pellet was solubilized in 0.1 M sodium
carbonate (pH 11.5) and incubated on ice for an hour.
Solubilized proteins were extracted after centrifugation
and the pellet was resuspended one more time in 0.1 M
sodium carbonate (pH 11.5). The three protein fractions
were denatured in 8 M urea, reduced in 5 mM Tris (2-car-
boxyethyl)phosphine hydrochloride (TCEP, Roche);
alkylated by 20 mM iodoacetamide (IAM), and digested
with proteinase K (Roche) for 4 hours at 37°C, in 0.1 M
Sodium Carbonate (pH 11.5) as described in Wu et al.
2003 [23]. Peptide mixture was analyzed as previously
described [24].
Targeted MS/MS approach
Nine proteins involved in key phospholipid biosynthesis
were selected (PFL0620c; MAL13P1.214; PF11_0257;
PF13_0253; PF14_0020; PF13_0092; MAL6P1.145;
PFI1370c; and MAL8P1.58). Ten peptides uniquely
matching these proteins were targeted for quantitation in
a directed MS/MS experiment. Treated and untreated par-
asites were lysed with 0.1 M Na2CO3, centrifuged for 30
minutes at 4°C, and fractionated into soluble and pellet
fractions. After adjusting the pH to 8.5, fractions were
denatured, reduced, alkylated and digested with endopro-
teinase Lys-C and trypsin as described previously [21].
The chromatography method entailed a six-step MudPIT
approach, and a custom MS method collecting MS/MS
spectra for each of the 10 targeted ions repeatedly. To esti-
mate the rate of false positives in the protein identification
analysis, MS/MS data were searched using SEQUEST
against a combined database containing P. falciparum and
Human/Mouse/Rat amino acid sequences as well as an
identical database where each protein sequence was rand-
omized. The length and amino acid composition of each
protein sequence remained the same, but the positions of
amino acids were altered. Thus any hits to the scrambled
protein sequences indicate false positives, and the overall
rate can be determined. Protein identification parameters
were adjusted to achieve a 5% false positive rate.
For the P. falciparum phosphoethanolamine methyltrans-
ferase, PfPMT, peptides derived from untreated and T4-
treated samples eluted in the same MudPIT cycle with
retention times that correlated with each other – eluting at
54 and 58 minutes for untreated and treated samples,
respectively. Extracted ion chromatograms (XICs) for the
y6, y8, y10, and y15 fragment ions of PfPMT peptide were
generated for the cycle in which they were identified using
a retention time window of two minutes (Data not
shown). Each individual XIC was smoothed using adja-
cent averaging, and the area under each was calculated.
The average ratio was 1.03 (untreated:treated) with a
standard deviation of 0.08.
For PfCEPT, 45 spectra were identified as PfCEPT peptide
in untreated sample and 1 spectra in T4-treated samples.
The single peptide identified in the treated sample had a
significantly different retention time (0.43 minutes) from
those identified in the untreated sample, which eluted
consistently near the end of the organic gradient (~113
minutes). An inconsistent retention time and manual
inspection of the MS/MS spectrum led us to believe the
peptide detected in the treated sample was a false positive.
XICs were generated for the y5, y6, y13, and y14 fragment
ions, which clearly indicate that this peptide elutes near
113 minutes in the untreated sample, whereas no signal
was detected for any of these fragment ions in the treated
sample near this retention time (Data not shown).
T4 effects on P. falciparuml phospholipid biosynthesis
P. falciparum-infected erythrocytes (3D7 strain) (5–7%
parasitemia, 5% hematocrit) were incubated in 150 μl of
choline-free RPMI 1640 supplemented with 25 mM
Hepes (pH 7.6) in the presence or absence of T4 at the
indicated concentration. After 30 minutes, 50 μl of
medium containing [3H]-choline (5 μM final concentra-
tion in 200 μl, 2 μCi/well), [3H]-ethanolamine (2 μM, 1
μCi/well) or [3H] hypoxanthine (1 μCi/well) were added.
Suspensions were incubated for 4 hours at 37°C in a 5%
CO2 incubator. Reactions were stopped at 4°C and cell
suspension washed 3 times with 0.9% NaCl. Phospholip-
ids were extracted according to a modified Folch protocol
[25,26] and the organic phase was fractionated by silica
gel thin-layer chromatography (TLC) with chloroform/
methanol/acetic acid/0.1 M sodium borate (75/45/12/Page 4 of 15
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radioactivity was measured by scintillation counting.
T4 effects on aqueous-soluble metabolites
P. falciparum-infected erythrocytes were incubated at 20 –
22% hematocrit and 5–10% parasitemia in a final volume
of 200 μl of choline-free RPMI 1640 supplemented with
25 mM Hepes (pH 7.6) in the presence or absence of T4.
[3H]-choline (20 μM) and [3H]-ethanolamine (2 μM)
were added at time 30 min. Suspensions were incubated
for 2.5 hours at 37°C in a 5% CO2 incubator. Water-solu-
ble metabolites were obtained from the aqueous superna-
tant according to the Folch protocol and were fractionated
by a silica gel TLC with methanol/water/30% NH4OH
(70/29/1) (Retention Factor Cho:0.02; P-Cho:0.18; P-
Etn:0.44; CDP-Cho and CDP-Etn:0.78). Spots were iden-
tified by comparison to co-migrating standards. All spots
were scraped off and amounts of radioactivity were deter-
mined by liquid scintillation counting. Results are
expressed as percents of control test without T4.
Results
Global transcriptional analysis of T4-treated P. falciparum
Consistent with those results reported previously for vari-
ous P. falciparum clones [14], T4 inhibited growth of the
3D7 strain with an IC50 of 1 nM. We were interested in the
biological effect of this drug at early stages of the lifecycle,
and over longer time periods. As such, highly synchro-
nized cultures were harvested 6, 12, 18, 24, 30, 36, 43, 48
and 71 hours after the addition of 0 or 40 nM T4 (> IC80
value), to allow morphological analysis, RNA isolation
and protein extraction (Figure 2). Short exposures (4
hours incubation time) with 40 nM T4 have been shown
to inhibit growth of ring and trophozoite stages by 99%
and 85%, respectively [14]. Despite the fact that short
drug exposure shows a potent non-reversible cytotoxic
effect [14], parasites were maintained in the presence of
the drug to avoid additional culture handling, parasite
stress (due to temperature changes) and loss of potential
transcriptional effects after washes. Whereas no morpho-
logical differences could be detected between untreated
and T4-treated parasites during the first 24 hours, signifi-
cant morphological abnormalities and arrest of the cell
cycle progression were observed between 30 and 71 hours
following addition of 40 nM T4. In these cultures, small
and dense trophozoites appeared and parasites failed to
enter schizogony (Figure 2). Parasitemia of treated cul-
tures decreased dramatically at 48 (3–4% parasitemia ver-
sus 10–12%) and 71 hours (0.5–1% parasitemia versus
10 – 12%). RNA extraction was performed on each sam-
ple in order to monitor global transcriptional profiles.
RNA samples were labeled and hybridized to the custom
malaria oligonucleotide array as previously described
[17]. No significant differences were detected between
untreated and T4-treated parasites during the first 18
hours of incubation at low drug concentration (2 nM and
20 nM (The correlation coefficient of the transcript expres-
sion values between untreated and T4-treated cultures was
0.99) – Data not shown). No significant changes after 5
hours of incubation with a high drug concentration (125
nM – Figure 3A and Additional file 2) were detected.
Hybridization studies performed with parasites incubated
with 40 nM of T4 for 24 hours resulted in a correlation
coefficient of 0.98 with a total of 137 genes showing
greater than 2-fold differential expression between
untreated and T4-treated parasites (PANOVA values for these
genes were lower than 0.05 (Additional file 3 and Figure
3B). Of the 137 genes, 99 were known to be expressed in
gametocytes, 21 were known to display strong variations
in the level of expression throughout the erythrocytic life
cycle and 17 showed a transcript level close to background
in treated and untreated parasites. None of these genes
were known or predicted to be involved in phospholipid
metabolism in P. falciparum (Figure 1). T4 treatment for
30 and 36 hours resulted in increased transcriptional
changes with 1140 and 1825 genes differentially
expressed, respectively (See Additional file 3). The correla-
tion coefficient of the expression values between
untreated and treated parasites at these time points
decreased significantly (r = 0.87 and 0.72 at 30 and 36
hours, respectively) (Figure 3C and 3D). However the cor-
relation coefficients observed between transcripts at dif-
ferent stages of the P. falciparum cell cycle without
treatment also changed significantly (i.e., 24 hours/30
hours, r = 0.64; 30 hours/36 hours, r = 0.95 and 24 hours/
36 hours, r = 0.95). To further understand these complex
transcriptional changes, data obtained from studies
involving T4 treatment were compared to those previ-
ously reported for the parasite intraerythrocytic life cycle
[17,19] using the ontology based pattern identification
algorithm (OPI) [20]. As illustrated in Figure 4, three
main categories of gene behavior emerged. The first cate-
gory includes genes already known to be expressed during
gametocytogenesis [19] (pattern A). These genes were
defined by the gene ontology groups GNF0004 (sexual
development), GO:0006633 (fatty acid biosynthesis in
apicoplast) or GO:0015630 (microtubule cytoskeleton).
The second category includes genes whose expression was
not significantly altered following treatment with T4 (pat-
tern B and D Figure 4). These include the following repre-
sentative GO clusters: GO:0030260 (cell invasion),
GO:0020008 (rhoptry), GO:0045177 (apical part of cell)
and GO:0030383 (host-pathogen interaction). The third
category (pattern C Figure 4) encompassed genes involved
in cell cycle and metabolism such as GO:0006006 (glu-
cose metabolism), GO:0019538 (protein metabolism),
GO:00063396 (RNA processing), GO:0007049 (cell
cycle) and GO:0006260 (DNA replication). The expres-
sion profile of the genes in this category in untreated par-
asites decreased during the trophozoite/schizontPage 5 of 15
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Giemsa-stained smears of T4-treated and untreated culturesFigure 2
Giemsa-stained smears of T4-treated and untreated cultures. T4 was added at 40 nM at the early ring stage. The mor-
phology of parasites in treated and untreated cultures is shown (early trophozoites, T0+24 h; late trophozoites, T0+30 h; sch-
izonts, T0+36 h; early ring stage, T0+43 h; late ring stage, T0+48 h; and trophozoites, T0+71 h). Morphological changes are 
clearly observed at 36 hours with absence of schizont formation (T0+36 h). Between 43 and 48 hours surviving parasites are 
blocked at the trophozoite stages. At 71 hours parasitemia falls to negligible level.
BMC Genomics 2008, 9:513 http://www.biomedcentral.com/1471-2164/9/513transition (30 and 36 hours), consistent with previous
reports. In contrast, in treated parasites, these genes exhib-
ited stable transcript levels at 30 and 36 hours. Impor-
tantly, although T4 and its analogs are known to interfere
with the synthesis of PC, no specific effect on the expres-
sion of the genes encoding enzymes of the CDP-choline
and SDPM pathways could be detected in response to the
drug (Additional file 4). RT-PCR analysis performed on
RNA isolated from untreated and T4-treated parasites con-
firmed the results of the microarray analyses (See Addi-
tional File 1). The complete cluster analysis as well as
various statistical parameters can be accessed from our
web page http://carrier.gnf.org/publications/T4/ or from
the PlasmoDB database http://plasmodb.org/.
Proteomic profiling
The lack of specific transcriptional regulation of the genes
involved in phospholipid metabolism following T4 treat-
ment led us to investigate the global effect of this com-
pound on the proteome. To estimate relative changes in
protein levels following treatment with T4, proteins were
extracted from cultures 24 hours after the addition of T4
at a concentration of 40 nM to ring-stage parasites. Protein
abundance was estimated by mass spectrometry analysis
{Zybailov, 2005 #341; Le Roch, 2004 #203; Florens, 2002
#112}. Protein identification was carried out in six exper-
iments, each consisting of three replicate analyses of
treated and untreated parasites. A total of 889 proteins
were identified, with 560 and 571 proteins identified
from T4 treated and untreated parasites, respectively
(Additional file 5). The Pearson correlation coefficient
was high (r = 0.932) compared to the Pearson correlation
Logarithm-transformed expression values of untreated versus treated P. falciparum culturesFi u e 3
Logarithm-transformed expression values of untreated versus treated P. falciparum cultures. A- The logarithm-
transformed expression values of untreated and treated (T4 = 125 nM) mixed population after 5 hours of incubation. B – C – 
D – The logarithm-transformed expression values of untreated and treated (T4 = 40 nM) synchronized population for 24, 30 
and 36 hours of incubation respectively (drug added at the ring stage).Page 7 of 15
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Hierarchical clustering of all 290 OPI clustersFigure 4
Hierarchical clustering of all 290 OPI clusters. Genes in each cluster share a similar expression pattern represented as a 
row in the heat map. The right panel is the zoom-in view of selected heat map sections with the six T4 data set further hori-
zontally expanded for ease of visual inspection. Bright red indicates highest expression; bright green indicates lowest expres-
sion (gene-wise normalized). Asexual S, T refers to the erythrocytic cycle expression profile analysis of malaria parasite 
synchronized using Sorbitol chemical treatment (S) or the thermo-cycling incubation (T) describes in Le Roch et al, 2003. Gene 
behaviors of T4-treatment can be characterized into three categories: Pattern A shows an induction in gametocytogenesis; Pat-
tern B and D shows no change in expression before and after T4 treatment; Pattern C shows an up regulation most likely due 
to DNA replication, metabolism and cell cycle progression. Some representative GO groups are shown next to the pattern.
BMC Genomics 2008, 9:513 http://www.biomedcentral.com/1471-2164/9/513coefficient observed between independent proteome
datasets of different stages of the P. falciparum life cycle
(i.e., ring/trophozoite, r = 0.534; trophozoite/schizont, r =
0.389 and schizont/ring, r = 0.506) [22]. The high corre-
lation coefficient observed between untreated and T4-
treated parasites correlates with the lack of observable
transcriptional changes at 24 hours post drug treatment.
Nevertheless, a small number of proteins showed subtle
differences in their relative abundance. Proteins predicted
to play a role in biological processes occurring in the food
vacuole, such as plasmepsin or falcipain, were enriched
amongst those proteins showing the most significant
increases. Four of the seven annotated food vacuole pro-
teins were among the top 64 of those that showed
increased peptide abundance in the T4 treated sample.
Conversely, with the exception of MSP1, many know
invasion proteins such as rhoptry proteins (RAP1, CLAG1,
and CLAG2) were found to be less abundant following
treatment with T4 (P = 8.47e-7). By focusing our analysis
on proteins significantly up-regulated in response to drug
treatment, 53 proteins were found to exhibit a 3-fold or
greater increase in expression level (as measured by the
ratio of spectral counts) or were detected only in the drug
treated samples. Of these 'over-expressed' proteins, nine
were proteins from surface antigen families. Their modu-
lation may represent an overall stress response of the par-
asite [28]. The glycerol-3-phosphate acyltransferase
(PFL0620c, PfGAT) and the acyl carrier protein homolog
(PFB0385w) were detected in the drug treated samples
only. In addition, the PfPMT, a key enzyme in the SDPM
pathway as well as the S-adenosylmethionine synthetase
(PFI1090w, which provides the PfPMT essential cofactor
S-adenosylmethionine), showed an increase in treated
versus untreated spectral counts (17 versus 5 spectra
counts for PfPMT and 7 versus 2 spectral counts for
PFI1090w in T4 treated and untreated parasites, respec-
tively). Using a semi quantitative MudPIT analysis, slight
differences in spectral counts are not always significant
and enzymes expressed at low levels are often difficult to
detect. To improve our analysis and perform a quantita-
tive proteomic analysis, we used a labeled isoleucine strat-
egy [29]. Unfortunately, this method proved unsuccessful
due to an irregular distribution of labeling efficiency for
all proteins even after two cell cycles (Data not shown).
This is most likely attributed to the incorporation of non-
labeled isoleucine from the human serum. To gain further
insight into the expression pattern of proteins involved in
phospholipid metabolism in the absence or presence of
T4, a targeted MS/MS approach was used. Ten peptides
derived from nine phospholipid metabolic enzymes were
selected (Additional file 6). PfPMT, and choline/eth-
anolamine-phosphotransferase (PfCEPT, MAL6P1.145;
involved in the final step of synthesis of PC via the choline
and SDPM pathways), were successfully detected [7]. The
difference in the levels of PfPMT peptides detected in
untreated (2 spectra) and T4-treated (6 spectra) parasites
was not highly significant. In the case of PfCEPT, however,
45 peptides were detected in the absence of T4 compared
whereas in the presence of the compound no peptide
spectra could be detected. This result suggests that the
expression of PfCEPT is severely reduced following treat-
ment with T4. Using the global proteomic approach as
well as the targeted MS/MS approach, no additional
known or predicted phospholipid metabolic enzymes
were detected. The abundance of these proteins may be
below the levels that can be detected using mass spec-
trometry.
To validate T4 specific effects on PC metabolism, the
incorporation of radiolabeled choline (Cho) and eth-
anolamine (Etn) into PC and phosphatidylethanolamine
(PE), and their intermediary water-soluble metabolites,
phosphocholine (P-Cho), phosphoethanolamine (P-
Etn), cytidine-diphospho-choline (CDP-Cho) and cyti-
dine-diphospho-ethanolamine (CDP-Etn) was moni-
tored in the absence or presence of the compound. As
shown in Figure 5A, choline-derived PC levels were
decreased by 50% in the presence of 0.8 μM T4. At this
concentration, the synthesis of PC from ethanolamine
was unaffected. Higher concentrations of T4, however,
resulted in a decrease in PC biosynthesis from eth-
anolamine. On the other hand, T4 had no affect on the
biosynthesis of PE or nucleic acid from ethanolamine or
hypoxanthine, respectively. Together these data suggest
that T4 treatment elicits a rapid and specific inhibition of
the synthesis of PC via the two main biosynthetic path-
ways. Analysis of the water-soluble intermediary metabo-
lites of PC biosynthesis following labelling with
[14C]choline showed that T4 treatment caused a major
decrease in the intracellular levels of radiolabeled choline
and of the downstream metabolites phosphocholine and
CDP-choline (Fig. 5B and 5C). This suggests that T4 may
have an effect on the transport of choline into the parasite
and may also inhibit the first two steps of the CDP-
choline pathway catalyzed by the the choline kinase,
PfCK1 and the phosphocholine citidylyltransferase,
PfCCT. The inhibition of choline transport is consistent
with previous studies that showed inhibition of choline
transport into P. falcparum-infected erythrocytes and yeast
by quaternary ammonium compounds [22,27]. The met-
abolic studies also showed that at T4 concentrations
above 1 μM the incorporation of radiolabeled eth-
anolamine into phosphocholine was significantly
decreased whereas ethanolamine phosphorylation was
not affected, suggesting an inhibition of at least one
enzyme downstream P-Etn i.e. PfPMT, CTP-phospho-
choline cytidylyltrasnferase (PfCCT) or PfCEPT.Page 9 of 15
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In the recent years, large-scale transcriptional profiling has
been used, with varying degrees of success, to gain a better
understanding of the mechanism of action of small mole-
cules [30-35]. Whereas this approach has sometimes been
challenging [36], in large part it has proven successful in
bacteria and the yeast Saccharomyces cerevisiae. In multicel-
lular organisms, large-scale transcriptional profiling ana-
lyzed under different stress conditions have proven more
difficult due to multiple cell types or tissues as well as
complex transcriptional regulations. In addition to tran-
scriptional profiling, proteomic approaches are also gain-
ing wide use as molecular tools to help unravel the mode
of action of various compounds [37-39]. In this study, we
have combined both approaches to study the response of
the human malaria parasite, P. falciparum, to exposure to
the bisthiazolium choline analog T4. Following exposure
to low concentrations (2, 20 nM, (data not shown) or
short incubations at 125 nM (30 minutes and 5 hours –
data not shown), no specific transcriptional changes were
observed, nor after a 5 hour treatment at a higher dose (T4
= 125 nM; Figure 2 and Additional File 2). Following a
longer incubation with 40 nM T4 (24, 30 and 36 hours)
no specific changes could be observed in the transcription
of genes involved in phospholipid metabolism. However,
changes due to an arrest of the cell cycle were significantly
detected after 30 and 36 hours of incubation with the
drug. To subtract the transcriptional changes due to cell
cycle effect, we analyzed the transcription profile obtained
at 24, 30 and 36 hours with previously published life cycle
data set [19,22] using the OPI algorithm [20]. A transcrip-
tional profile reminiscent of a global drug-induced stress
response was detected when compared to untreated cul-
tures (Figure 4). This profile is characterized by an appar-
ent arrest of the cell cycle and a significant induction of
genes known to be expressed in gametocytes [17,19]. This
cell cycle arrest could signify a major shift of the parasite
from asexual development to sexual differentiation.
Although more than 5,000 infected red blood cells were
analyzed, no gametocytes could be observed in the treated
cultures, suggesting a specific induction of expression of
genes involved in sexual differentiation and development
rather than production of gametocytes in the culture fol-
lowing drug treatment. Gametocytogenesis can be
induced by various external factors both in vitro and in
vivo, most of which are conditions that cause physiologi-
cal stress on the parasite, such as treatment with antima-
larial drugs [40-45]. Thus, the changes in gene expression
observed as a result of T4 treatment might indicate an
attempt by the parasite to commit to sexual differentia-
tion. The lack of gametocytes following treatment with T4
could, however, be due to the potent activity of quater-
nary ammonium compounds against this stage of the par-
asite's life cycle or the time taken to produce gametocytes
post commitment to gametocytogenesis. However, G25,
the first generation lead compound [13] was shown to
prevent P. falciparum sexual differentiation and to prevent
parasite transmission by altering gametocyte maturation,
exflagellation and sporogony (H. Vial, personal commu-
nication). Using the OPI algorithm, our data showed that,
once changes due to the cell cycle and stress related
(gametocytogenesis) genes were subtracted, T4 treatment
led to no specific or compensating changes in transcrip-
tion under the experimental conditions described herein.
It is possible, however, that a longer exposure to a lower
drug concentration could reveal a parasite specific
response. Using such a condition, Dahl et al [46] were suc-
cessful in their use of transcriptome analysis to identify
the effects of tetracycline on the P. falciparum apicoplast
after more than 48 hours of treatment.
Global proteomic profiles of untreated and T4-treated
parasites after 24 hours suggested that T4 treatment leads
to an induction of those proteins localized to the food
vacuole. As choline analogs have been shown to accumu-
late within the parasite digestive vacuole and possibly
Biochemical effect of the bisthiazoliums T4F gur  5 (se  previ us page)
Biochemical effect of the bisthiazoliums T4. A- Effect of T4 on the biosynthesis of phospholipids and nucleic acids. P. fal-
ciparum trophozoite-infected erythrocytes were incubated in the presence of the indicated concentrations of T4 at time 0 and 
radioactive choline (5 μM), ethanolamine (2 μM) and hypoxanthine were added at time 30 min. Incorporation of the radioac-
tive precursors into their corresponding macromolecules at time 4 h are expressed as percentage of those measured in 
infected erythrocytes incubated without T4 and are means of 4 experiments ± SEM. In the absence of drugs, choline incorpo-
ration into PC was 4.71 ± 0.26 nmol/1010 cells/hour, and ethanolamine incorporation into phosphatidylethanolamine PE and 
into PC (indicated as PC*) was 14.3 ± 0.33 and 1.97 ± 0.16 nmol/1010 cells/hour. Effects of T4 on choline (B) and ethanolamine 
(C) water-soluble metabolites. P. falciparum-infected erythrocytes were incubated in the presence of the indicated concentra-
tions of T4 at time 0. Radioactive choline (20 uM) and ethanolamine (2 uM) were added at time 30 min and reactions were 
stopped at time 2.5 hours. Incorporation of the radioactive precursors into their corresponding metabolites is expressed as 
percentage of those measures in infected cells incubated without T4 and are means of 4 experiments ± SEM. In the absence of 
drugs, intracellular choline, phosphocholine and CDP-choline were respectively 1.1 ± 0.1, 23.7 ± 0.5 and 0.30 ± 0.01 nmol/1010 
cells/hour. In C, phosphorylethanolamine and phosphocholine and the sum CDP-choline + CDP ethanolamine were respec-
tively 4.90 ± 0.25 and 1.86 ± 0.07 and 0.77 ± 0.06 nmol/1010 cells/hour. Incorporation of Eth into P-ETn is not affected by T4.Page 11 of 15
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these enzymes potentially validate this interaction. A
decrease in the levels of invasion proteins such as those
localized to the rhoptry or the peripheral surface of the
parasites was also detected. This could suggest a cell cycle
arrest at the protein level even thought no significant tran-
scriptional changes were detected for such proteins. To
assess the effect of T4 on the expression of enzymes
involved in phospholipid metabolism, changes in protein
levels using a targeted MS/MS approach was applied. The
proteomic data indicated a significant decrease in the
abundance of PfCEPT, a protein involved in the final step
of phosphatidylcholine synthesis. Nonetheless, no
PfCEPT transcriptional changes could be detected at 24
hours using RT-PCR analysis (data not shown). Previous
studies have shown a significant discrepancy between
mRNA and protein levels, suggesting a major role for post-
transcriptional events within the parasite life cycle
[22,48,49]. One possible explanation for the effect of T4
on PfCEPT is that the expression of PfCEPT could be
directly controlled by the amounts of CDP-choline avail-
able.
Metabolic studies showed that T4 inhibits the biosynthe-
sis of PC but not that of PE or DNA. This finding is con-
sistent with previous reports that showed a specific
inhibition of PC biosynthesis by quaternary ammonium
compounds [11,14,50-52]. Previous studies have shown
that T4 accumulates to 200 to 300-fold in Plasmodium-
infected erythrocytes within two hours [14]. This suggests
that the concentrations used in the metabolic studies are
within the range of the intracellular concentration of the
compound, and that the pathways for synthesis of PC
from both choline and ethanolamine are the targets of the
compound. These biochemical analyses showed that T4
treated parasites had low levels of intracellular choline,
phosphocholine and CDP-choline. This suggests that T4
inhibits choline transport and may also act by inhibiting
the steps of the CDP-choline pathway catalyzed by the
choline kinase PfCK and the phosphocholine cytidy-
lytransferase, PfCCT. The inhibition of choline entry into
the parasite is consistent with previous findings that
showed that this class of compounds are potent inhibitors
of choline transport into Plasmodium-infected erythro-
cytes and into the parasite [52,53]. The metabolic studies
also showed that at a slightly higher concentration T4
inhibited the synthesis of phosphocholine from eth-
anolamine with no effect on the synthesis of phosphoeth-
anolamine or CDP ethanolamine. This point out an
additional effect of T4 that also inhibiting PC biosynthesis
from ethanolamine through an action on one step down-
stream P-Etn, i.e. PfPMT, CTP-phosphocholine cytidylyl-
transferase (PfCCT) or PfCEPT. In vitro studies indicated
that millimolar concentrations of the bisthiazolium are
required to dose-dependently inhibit the PfCCT and
PfCEPT (unpublished). Thus, the very high accumulation
of the choline analogues into the blood stage of the malar-
ial parasite [13,14], can lead to in situe concentration able
to interfere with parasite choline uptake and PC biosyn-
thetic enzymes. The specificity of inhibition by T4 towards
enzymes of the CDP-choline pathway and eventually
PfPMT whose substrates or products contain a choline
moiety could thus be directly linked to its structural prop-
erties. Future structural studies aimed to characterize the
interaction between T4 and these enzymes are warranted.
The proteomic data indicated that PfCEPT protein levels
decreased significantly following treatment with T4.
Taken together these findings suggest that PfCEPT expres-
sion or stability might be directly regulated by the availa-
bility of CDP-choline. Recent studies have provided
evidence for the regulation of the expression and stability
of PfPMT in response to exogenous choline [54]. It is pos-
sible that PfCEPT might also be subjected to posttransla-
tional regulation by its substrate CDP-choline. Low
amounts of this substrate due to direct inhibition of
PfCCT or other earlier steps of the CDP-choline and
SDPM pathways could result in the inhibition of synthesis
or increased degradation of PfCEPT.
In conclusion, despite the absence of highly significant
transcriptional changes within the metabolic pathways
targeted by T4, this analysis validates the existence of a
specific transcriptional cascade across the P. falciparum cell
cycle [17,55]. The malaria parasite, as an obligate intracel-
lular parasite, has evolved within a buffered intracellular
environment where evolutionary forces may have
induced the loss of specific transcriptional feedback
responses. Proteomic and biochemical studies indicate a
decreased level of PfCEPT, suggesting a specific mecha-
nism of inhibition of PC biosynthesis. Together, these
results emphasize the importance of post-transcriptional
regulation in parasite drug response. The nature of such
modifications has been largely unexplored in P. falci-
parum. It can involve mRNA stability, phosphorylation, as
well as an increase in protein instability and degradation
via the ubiquitin/proteasome pathway. Further experi-
ments will be required to characterize the mechanisms
involved in such post-transcriptional regulations.
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